©2024 淇嘉. All Rights Reserved.
首页 / 产品 / iLiver
  • Day-25 iLivers represent uniformly sized 3D spheroids, which consists of hepatocytes (ALB+), cholangiocytes (CK7+), Kupffer cells (CD68+) and hepatic stellate cells (VIM+), as identified by immunofluorescence. Scale bar = 100 μm.
  • Day-25 iLivers represent uniformly sized 3D spheroids, which consists of hepatocytes (ALB+), cholangiocytes (CK7+), Kupffer cells (CD68+) and hepatic stellate cells (VIM+), as identified by immunofluorescence. Scale bar = 100 μm.
  • The expression of genes related to cytochrome P450-mediated drug metabolism based on RNA-seq data.

即用型 iPSC 肝类器官,3d0120

  • 使用 “人多能干细胞向肝类器官分化系统 (Cat. 3d0020)” 诱导分化产生

  • 呈大小均一的球状结构,具有肝细胞、 胆管细胞、肝巨噬细胞、肝星状细胞等4种细胞类型

  • 已验证>20种肝脏功能,包括白蛋白/尿素分泌、糖原储存、脂质代谢、P450 药物代谢酶活性与可诱导性等

  • 适合作为肝病机制研究、药物筛选、组织修复的精准人源工具


产品规格

  • 1800个 iLivers
  • 3600个 iLivers
  • 7200个 iLivers
  • 14400个 iLivers
  • 定制 iLiver

简介

 “ 即用型 iPSC 肝类器官 是以人诱导多能干细胞(iPSC, induced pluripotent stem cells)为起点细胞,基于肝脏发育进程的关键分子信号,凭借 iPSC 谱系共分化技术诱导分化形成。iLiver 具有更接近人真实肝脏的细胞谱系及结构特征,为肝脏发育机制的探索、肝病模拟、药物开发与评价等研究提供可靠的模型工具。

无边框表格

遗传信息






• 类器官类型:• 来源:   • 性别:

   肝类器官  成纤维细胞  女

• 捐助者状态: • 年龄:

   健康  20

性能数据

Characteristics

即用型 iPSC 肝类器官,3d0120(图1)


Day-25 iLivers represent uniformly sized 3D spheroids, which consists of hepatocytes (ALB+), cholangiocytes (CK7+), Kupffer cells (CD68+) and hepatic stellate cells (VIM+), as identified by immunofluorescence. Scale bar = 100 μm.




Application of iLiver Organoids


即用型 iPSC 肝类器官,3d0120(图2)


Modeling NASH using day-24 iLivers manifested excessive accumulation of fibrosis (a-SMA staining), along with an increased secretion level of clinical fibrosis marker PIIINP by ELISA analysis.




Drug Metabolism in iLivers



即用型 iPSC 肝类器官,3d0120(图3)


The expression of genes related to cytochrome P450-mediated drug metabolism based on RNA-seq data.



参考文献

  • Tadokoro T, Murata S, Kato M, et al. Human iPSC–liver organoid transplantation reduces fibrosis through immunomodulation[J]. Science Translational Medicine, 2024, 16(757): eadg0338.

  • Zhang C J, Meyer S R, O’Meara M J, et al. A human liver organoid screening platform for DILI risk prediction[J]. Journal of hepatology, 2023, 78(5): 998-1006.

  • Guan Y, Enejder A, Wang M, et al. A human multi-lineage hepatic organoid model for liver fibrosis[J]. Nature communications, 2021, 12(1): 6138.

  • Wu D, Chen X, Sheng Q, et al. Production of functional hepatobiliary organoids from human pluripotent stem cells[J]. International journal of stem cells, 2021, 14(1): 119-126.

  • Wu F, Wu D, Ren Y, et al. Generation of hepatobiliary organoids from human induced pluripotent stem cells[J]. Journal of Hepatology, 2019, 70(6): 1145-1158.  

产品推荐

联系我们